

## ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

### First UK Deployment at Mid Yorkshire Teaching NHS Trust reduces SSI rates by 71% with Steriwave Nasal Photodisinfection

Ondine Biomedical Inc. (LON: OBI) reports that results from the first NHS deployment of Steriwave<sup>®</sup> nasal decolonization technology at Mid Yorkshire Teaching NHS Trust (Mid Yorks) have demonstrated a substantial reduction in surgical site infections (SSI) following elective knee and hip replacement surgery. A new health economic analysis conducted by the world-renowned York Health Economics Consortium (YHEC) also found that Mid Yorks' use of Steriwave is cost-saving for hip and knee replacement surgery.

Mid Yorks' analysis of data from a six-month period demonstrated that Steriwave significantly reduced the combined rate of SSI in elective hip and knee replacement surgeries by 71.4%, from a baseline rate of 1.40% to 0.42%. The results from knee replacements were particularly impressive, showing a reduction to zero from 2.3% ( $p=0.014$ ). The number of hip replacement surgeries during the period was insufficient for statistical analysis. In both orthopaedic procedures, Steriwave was deployed in addition to the current standard of care which included octenidine antiseptic nasal gel and chlorhexidine body wash.

Using real-world data from Mid Yorks, the YHEC health economic analysis showed that in a standardized cohort of 1,000 people, Steriwave prevents a total of 9.8 SSIs more than standard of care alone, saves £2,869 and reduces the overall number of hospital bed days by 139. Alongside the YHEC health economic analysis, survey data collected at Mid Yorks revealed high levels of satisfaction with Steriwave among both staff and patients, with a strong likelihood of recommendation.

#### Carolyn Cross, CEO of Ondine Biomedical, commented:

*"We commend Dr. Stuart Bond and the team at Mid Yorkshire Trust's Pontefract Hospital for their forward-thinking approach to innovation and commitment to tackling the persistent challenge of hospital-acquired infections and antibiotic resistance. We anticipate that MYTT's early adoption of this technology in the UK will serve as an influential example for healthcare institutions globally, promoting the pursuit of improved patient outcomes and better patient throughput while mitigating the risks associated with antimicrobial resistance."*

Steriwave is a non-invasive and painless nasal decolonization treatment that uses a proprietary light-activated antimicrobial agent to destroy harmful pathogens, including bacteria, viruses, and fungi, in the nose. Steriwave treatment involves applying a proprietary photosensitive agent to each nostril with a nasal swab, followed by illumination with a specific wavelength of red light for five minutes. The treatment is effective immediately and takes less than five minutes.

The YHEC economic analysis was commissioned by Health Innovation Network Yorkshire and Humber and Ondine Biomedical as part of a project to better understand the health economic impact of using Steriwave in the UK. Full details of the analysis are currently being prepared for publication.

#### Enquiries:

Ondine Biomedical Inc.

Carolyn Cross, CEO

[www.ondinebio.com](http://www.ondinebio.com)

Via Vane Percy & Roberts

#### Strand Hanson Limited (Nominated & Financial Adviser)

James Harris, Richard Johnson

+44 (0)20 7409 3494

#### RBC Capital Markets (Broker)

Rupert Walford, Kathryn Deegan

+44 (0)20 7653 4000

#### Vane Percy & Roberts (Media Contact)

Simon Vane Percy, Amanda Bernard

+44 (0)77 1000 5910

#### About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies (also known as 'photodisinfection'). Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is approved in Canada and several other countries under the name Steriwave<sup>®</sup>. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.

#### About Mid Yorkshire Teaching NHS Trust

The UK's Mid Yorkshire Teaching NHS Trust provides acute, community and specialist health care services to around half a million people living in Wakefield and North Kirklees. It has three hospitals at Dewsbury, Pontefract and Wakefield (Pinderfields), and also provide care in community settings such as GP surgeries, health centres and clinics as well as in people's own homes.

**About York Health Economics Consortium (YHEC):**

York Health Economics Consortium (YHEC) is a health economic consulting company formed in 1986 and wholly owned by the University of York. YHEC is the University of York's main consultancy provider of health economics expertise.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@lseg.com](mailto:ms@lseg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAPKBBNPBKKAQK